Cannabis REITs cash in on rescheduling deals

By mid-2026, the anticipated federal rescheduling of medical cannabis from Schedule I to Schedule III emerged as a pivotal regulatory catalyst poised to transform the cannabis real estate landscape. This shift would enable cannabis tenants to deduct normal business expenses, a change expected to significantly improve tenant credit quality by enhancing free cash flow and strengthening balance sheets. Companies like NewLake Capital Partners stand to benefit directly, as improved tenant financial health could lead to easier re-leasing processes and more reliable rent collections, thereby laying a stronger foundation for sustained financial and operational growth within the sector.

By mid-2026, NewLake Capital Partners exemplified how cannabis-focused REITs are navigating market dynamics through a strategic focus on stable, income-generating real estate assets. Managing a portfolio of 34 properties primarily under triple-net leases, NewLake leverages sale-leaseback and build-to-suit projects to provide essential capital to cannabis operators, underpinning its ability to sustain an 11% annualized dividend yield supported by 100% rent collection. This approach highlights the company’s commitment to balancing growth with risk mitigation amid an evolving regulatory landscape.

Despite facing a 6.5% year-over-year revenue decline in Q2 2026 due to some vacant properties, NewLake Capital demonstrated resilience by maintaining full rent collection and reporting net income of $5.9 million on $12.1 million in revenue. This financial stability allowed the company to uphold its dividend payout of $0.43 per share, signaling confidence in its portfolio’s long-term viability. The upcoming earnings call scheduled for August 6, 2026, further underscores NewLake’s transparency and proactive investor engagement amid these market headwinds.

In July 2026, Chicago Atlantic Real Estate Finance, Inc. executed a landmark $62.5 million second-lien financing deal with Koach Properties, secured by 32 single-tenant, triple-net leased cannabis retail properties spanning nine states. This sizable transaction not only underscores the growing sophistication of capital markets in cannabis real estate but also reflects a strategic alignment with the sector's evolving regulatory landscape, positioning Chicago Atlantic to capitalize on anticipated market improvements.

The innovative financing structure uniquely blends debt and equity by exchanging the second-lien notes for over 4.3 million shares of Chicago Atlantic’s common stock, valued at $14.53 per share, signaling a novel approach to leveraging equity rather than traditional cash in cannabis real estate deals. Coupled with tailored terms—10% annual cash interest, 2% payment-in-kind interest, a 2.5x exit fee, and an average 12-year maturity—this deal exemplifies bespoke financing strategies designed to navigate the complexities and uncertainties of the cannabis leasing market amid ongoing regulatory progress.

SNDL Inc.'s strategic acquisition of U.S. medical cannabis assets from Parallel—spanning 56 retail locations and three cultivation sites across Florida, Texas, and Massachusetts—signals a bold repositioning to become one of the first plant-touching cannabis companies directly operating in the U.S. This move, centered exclusively on medical cannabis operations and deliberately excluding adult-use businesses, aligns with evolving regulatory frameworks and Nasdaq's listing requirements, positioning SNDL for a potential Nasdaq debut following the DEA's rescheduling of medical cannabis to Schedule III.

The acquisition emerged from a complex multi-year debt restructuring that transformed SNDL's non-performing credit investment into controlling operational stakes, effectively extinguishing $842 million of Parallel's debt. This financial maneuver not only underscores SNDL's evolution from creditor to active operator through its Sunstream Bancorp arm but also exemplifies how cannabis companies are leveraging financial engineering to gain operational control and capitalize on the burgeoning U.S. medical cannabis market.